ChemicalBook > CAS DataBase List > Obinutuzumab

Obinutuzumab

Product Name
Obinutuzumab
CAS No.
949142-50-1
Chemical Name
Obinutuzumab
Synonyms
Ga 101;Ro5072759;afutuzumab;Ro 5072759;Humab(cd20);Obinutuzumab;Obinutuzumab/afutuzumab;Obinutuzumab (anti-CD20);Research Grade Obinutuzumab;Obinutuzumab - Buffer solution
CBNumber
CB81518489
Formula Weight
0
MOL File
Mol file
More
Less

Obinutuzumab Property

form 
Liquid
color 
Colorless to light yellow
More
Less

Safety

Hazardous Substances Data
949142-50-1(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Biosynth Carbosynth
Product number
BO165592
Product name
Obinutuzumab - Buffer solution
Packaging
1mg
Price
$600
Updated
2021/12/16
More
Less

Obinutuzumab Chemical Properties,Usage,Production

Description

In November 2013, the US FDA approved the glycoengineered, type II anti-CD20 antibody obinutuzumab (also known as GA101) in combination with chlorambucil chemotherapy for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL). Obinutuzumab is the first drug approved under the FDA’s breakthrough therapy designation, created in 2012 to quicken the pace of development and review of drugs for serious conditions. The Fc portion of obinutuzumab was glycoengineered to reduce fucosylation of the Fc carbohydrate, resulting in increased FcγRIIIa affinity and antibody-dependent cellular cytotoxicity (ADCC) potency. As expected for a type II antibody, obinutuzumab demonstrated lower complement-mediated cytotoxicity, more potent mediation of cell death via the nonclassical apoptosis pathway and increased ADCC as compared with rituximab in preclinical studies. In addition, obinutuzumab induced a stronger antitumor effect in mouse xenograft models of human lymphoma than rituximab and ofatumumab, supporting clinical investigation of this third generation anti-CD20 antibody.

Originator

GlycArt Biotechnology AG (United States)

Uses

Obinutuzumab (GA101) a Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.

brand name

Gazyva

in vivo

Obinutuzumab is more active than rituximab administered at similar doses on established RL tumors. The antitumor effect of obinutuzumab against RL xenografts is dose dependent in terms of tumor growth inhibition (TGI). TGI is calculated using NCI formula at day 34 and shows values of 25, 75, and 85% for the 10, 30, and 100 mg/kg dosages of obinutuzumab, respectively. The higher doses of 30 and 100 mg/kg of obinutuzumab significantly inhibit the growth of RL tumors and result in some complete tumor remissions (10% and 30%, respectively). Tolerability of obinutuzumab with these regimens is excellent and no significant modification of body weight is observed[2]. Obinutuzumab induces a strong antitumor effect, including complete tumor remission in the SU-DHL4 model and overall superior efficacy compared with both rituximab and ofatumumab[1]. Obinutuzumab plus bendamustine achieves superior tumor growth inhibition versus rituximab plus bendamustine and shows a statistically significant effect versus the respective single treatments. Obinutuzumab plus chemotherapy is superior to the respective monotherapies[3].

References

[1] Herter S, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013 Oct;12(10):2031-42. DOI:10.1158/1535-7163.MCT-12-1182
[2] Dalle S, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody -GA101. Mol Cancer Ther. 2011 Jan;10(1):178-85. DOI:10.1158/1535-7163.MCT-10-0385
[3] Herting F, et al. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab(GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leuk Lymphoma. 2014 Sep;55(9):2151-5160. DOI:10.3109/10428194.2013.856008

Obinutuzumab Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Obinutuzumab Suppliers

Wuhan Sunrise Technology Development Co., Ltd.
Tel
27-027-83314682 13554138826
Fax
+86 (27) 8331-4682
Email
whsrtech@vip.163.com
Country
China
ProdList
246
Advantage
62
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
Country
China
ProdList
4747
Advantage
58
LUCKY PHARMA CO., LIMITED
Tel
0571-86403260 86403970
Fax
0571-86403970
Email
lucky@lkbiology.com
Country
China
ProdList
243
Advantage
58
Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Fax
021-65675885
Email
info@efebio.com
Country
China
ProdList
9803
Advantage
58
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Fax
QQ:3008007432
Email
3008007409@qq.com
Country
China
ProdList
71826
Advantage
60
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
8000
Advantage
62
Twochem Co.Ltd.
Tel
021-58111628 15800915896
Fax
QQ 3285589261
Email
sales@twochem.com
Country
China
ProdList
1788
Advantage
58
Tianjin Kaifu Pharmaceutical Technology Co., Ltd.
Tel
18081075745
Email
chemflowtech@sina.com
Country
China
ProdList
1886
Advantage
58
Guangzhou Hongyuan Chemical Co.,Ltd
Tel
15817493340
Email
981810490@qq.com
Country
China
ProdList
1566
Advantage
58
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Fax
QQ:422450190
Email
422450190@qq.com
Country
China
ProdList
10308
Advantage
58
Abmole Bioscience Inc.
Tel
021-50967598 02150967598
Email
sales@abmole.cn
Country
China
ProdList
4494
Advantage
58
Jiangxi ravel Biotechnology Co.,Ltd
Tel
400-880-2824; 13184580281
Fax
400-880-2824
Email
hj@ruiweier.cn
Country
China
ProdList
2686
Advantage
58
Hubei Kele Fine Chemical Co., Ltd
Tel
027-59101668 19945030958
Fax
027-59101668
Email
2881924765@qq.com
Country
China
ProdList
7936
Advantage
58
Wuhan Augda Biotechnology Co., Ltd
Tel
15071299552
Fax
QQ:262933239
Email
262933239@qq.com
Country
China
ProdList
7047
Advantage
58
Jiangxi ravel Biotechnology Co.,Ltd
Tel
185-0276-2003 18502762003;
Email
435918333@qq.com
Country
China
ProdList
2213
Advantage
58
Wuhan Yingnuo Pharmaceutical Technology Co., Ltd.
Tel
15387063101
Email
2881924050@qq.com
Country
China
ProdList
9957
Advantage
58
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
Country
China
ProdList
24961
Advantage
58
Biolab Reagents
Tel
027-65279366 18108604356
Email
products@biolabreagent.com
Country
China
ProdList
9868
Advantage
58
Wuhan Jingkangen Biomedical Technology Co., Ltd
Tel
13720134139 086-15871494362 13720134139
Email
orders@jknbiochem.com
Country
China
ProdList
6762
Advantage
58
Shanghai?Medlife?Pharm-Tech?Co.,?Ltd
Tel
021-59167510 18117107507
Email
vip@med-life.cn
Country
China
ProdList
5002
Advantage
58
Shanghai Aladdin Biochemical Technology Co.,Ltd.
Tel
400-6206333 13167063860
Email
anhua.mao@aladdin-e.com
Country
China
ProdList
48457
Advantage
58
Shanghai jerryxing Biomedical Technology Co., Ltd
Tel
17721492509; 17721492509
Email
643638326@qq.com
Country
China
ProdList
4970
Advantage
58
Changsha Fuzhen Biotechnology Co.,LTD
Tel
0731-13823398 15111215862
Email
313359644@qq.com
Country
China
ProdList
4161
Advantage
58
Wanxin Biotechnology (Jiaxing) Co., LTD
Tel
0573-83568680 18057391398
Email
3956524501@qq.com
Country
China
ProdList
1442
Advantage
58
Atagenix Laboratories
Tel
027-87008169 17762441161
Email
info@atagenix.com
Country
China
ProdList
10001
Advantage
58
Sangon Biotech (Shanghai) Co.,Ltd.
Tel
400-821-026
Email
Sales@sangon.com
Country
China
ProdList
6710
Advantage
58
AntibodySystem Laboratories SAS
Tel
33175446423
Email
support@antibodysystem.com
Country
China
ProdList
6739
Advantage
58
Biosynth Biological Technology (Suzhou) Co Ltd
Tel
51288865780
Email
sales@biosynth.com
Country
China
ProdList
6051
Advantage
58
Selleck Chemicals
Tel
400-668-6834
Email
info@selleck.cn
Country
China
ProdList
6071
Advantage
58
Cell Sciences
Tel
9785721070
Email
info@cellsciences.com
Country
China
ProdList
6308
Advantage
58
Wuhan Topule Biopharmaceutical Co., Ltd
Tel
+8618327326525
Email
masar@topule.com
Country
China
ProdList
8467
Advantage
58
Chongqing Haoyu Biotechnology Co., Ltd.
Tel
18983828904
Country
CHINA
ProdList
114
Advantage
58
Guangzhou Xinrong Biotechnology Co., Ltd
Tel
15919646073
Country
CHINA
ProdList
138
Advantage
58
Henan Surui Pharmaceutical Technology Co., Ltd
Tel
0371-58685969
Country
CHINA
ProdList
180
Advantage
58
Guangzhou Chuangze Biotechnology Co., Ltd.
Tel
18312220236
Country
CHINA
ProdList
178
Advantage
58
Proteintech China
Tel
--
Fax
--
Email
Proteintech-CN@ptglab.com
Country
CHINA
ProdList
6290
Advantage
58
Zhejiang Holypharm Biotech Co., Ltd
Tel
--
Fax
--
Email
liujin1227@126.com
Country
China
ProdList
414
Advantage
30

949142-50-1, ObinutuzumabRelated Search:


  • Ga 101
  • Humab(cd20)
  • Ro 5072759
  • Ro5072759
  • afutuzumab
  • Obinutuzumab/afutuzumab
  • Obinutuzumab
  • Research Grade Obinutuzumab(DHC90704)
  • Inhibitor,GA 101,Anti-Human CD20 type II, Humanized Antibody,inhibit,GA101,Obinutuzumab,GA-101
  • Obinutuzumab (anti-CD20)
  • Research Grade Obinutuzumab
  • Obinutuzumab - Buffer solution
  • 949142-50-1